Abstract
No public abstract is available from the verified source records.
Chen-Wei Liang, Yao‐Tung Lee, Jiunn-Kae Wang
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Validation of the craving scale in a large sample of adults with substance use disorders
10.1016/j.addbeh.2020.106651 · 2021
Recurrent alcohol-associated hepatitis is common and is associated with increased mortality
10.1097/hep.0000000000000825 · 2024
The dopamine motive system: implications for drug and food addiction
10.1038/nrn.2017.130 · 2017
Rational design of a combination medication for the treatment of obesity
10.1038/oby.2008.461 · 2009
Neurocircuitry modulating drug and alcohol abuse: a preface
10.1016/j.neuropharm.2022.109200 · 2022
A preliminary, open-label study of naltrexone and bupropion combination therapy for treating binge drinking in human subjects
2020
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects
10.1016/j.addbeh.2009.10.017 · 2010
Naltrexone/bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study
2013
Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis
10.1001/jama.2023.19761 · 2023
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
Review of acamprosate pharmacokinetics and dosing strategies
10.9740/mhc.2025.04.056 · 2025
The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder
10.1176/appi.ajp.2017.1750101 · 2018
Safety and tolerability of injectable extended-release naltrexone for the management of alcohol use disorder in advanced alcohol-associated liver disease
10.1111/apt.70237 · 2025
Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects
10.1038/sj.npp.1301440 · 2008
Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects
10.1111/j.1530-0277.2011.01565.x · 2011
Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans
10.1038/mp.2011.29 · 2011
Clinical characteristics and outcomes associated with bupropion overdose: a Canadian perspective
10.1080/15563650.2019.1699658 · 2020
Efficacy of mirtazapine in preventing intrathecal morphine-induced nausea and vomiting after orthopaedic surgery
10.1111/j.1365-2044.2010.06561.x · 2010
Efficacy of mirtazapine in preventing intrathecal morphine-induced nausea and vomiting after orthopaedic surgery
10.1111/j.1365-2044.2010.06561.x · doi-reference
Clinical characteristics and outcomes associated with bupropion overdose: a Canadian perspective
10.1080/15563650.2019.1699658 · doi-reference
Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans
10.1038/mp.2011.29 · doi-reference
Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects
10.1111/j.1530-0277.2011.01565.x · doi-reference
Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects
10.1038/sj.npp.1301440 · doi-reference
The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder
10.1176/appi.ajp.2017.1750101 · doi-reference
Review of acamprosate pharmacokinetics and dosing strategies
10.9740/mhc.2025.04.056 · doi-reference
Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis
10.1001/jama.2023.19761 · doi-reference
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects
10.1016/j.addbeh.2009.10.017 · doi-reference
Neurocircuitry modulating drug and alcohol abuse: a preface
10.1016/j.neuropharm.2022.109200 · doi-reference
Rational design of a combination medication for the treatment of obesity
10.1038/oby.2008.461 · doi-reference
The dopamine motive system: implications for drug and food addiction
10.1038/nrn.2017.130 · doi-reference
Recurrent alcohol-associated hepatitis is common and is associated with increased mortality
10.1097/hep.0000000000000825 · doi-reference
Validation of the craving scale in a large sample of adults with substance use disorders
10.1016/j.addbeh.2020.106651 · doi-reference
Safety and tolerability of injectable extended-release naltrexone for the management of alcohol use disorder in advanced alcohol-associated liver disease
10.1111/apt.70237 · doi-reference